Clincosm LogoSign in Get a demo

ER Positive Breast Cancer

Showing 1 - 11 of 11
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

Not yet recruiting
  • Breast Cancer
  • +4 more
  • (no location specified)
Aug 31, 2023

Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

Recruiting
  • Premenopausal Breast Cancer
  • +2 more
  • Taipei City, Taiwan
    Department of Oncology, National Taiwan University Hospital
Feb 7, 2023

Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)

Recruiting
  • Breast Cancer
  • ER Positive Breast Cancer
  • Letrozole 2.5mg
  • Lebanon, New Hampshire
  • +1 more
Dec 19, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Stanford, California
    Stanford University
Nov 16, 2022

Immune Environment in Response to Therapy in Breast Cancer

Recruiting
  • Breast Cancer
  • +3 more
  • Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
  • Philadelphia, Pennsylvania
    Abramson Cancer Center
Sep 15, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer Trial (Neratinib, Letrozole (L) or Anastrozole (A),

Not yet recruiting
  • Breast Cancer
  • +3 more
  • (no location specified)
Jan 11, 2022

Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Boston (NERATINIB,

Not yet recruiting
  • Stage IV (Metastatic) Breast Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 25, 2021

Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer Trial in Prato (Thymidine kinase activity)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Thymidine kinase activity
  • Prato, Tuscany, Italy
    Hospital Santo Stefano
Dec 10, 2020

D4 Choline Breast PET/CT

Not yet recruiting
  • HER2-negative Breast Cancer
  • +2 more
  • Imaging scan
  • London, United Kingdom
    Imperial College Healthcare NHS Trust/ Imperial College london
May 26, 2020

Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer Trial (AUY922)

Withdrawn
  • Breast Cancer
  • +3 more
  • (no location specified)
May 5, 2017